OncologyConsults



Considerations for Using Immune Therapy in Treating
Metastatic Non-Small Cell Lung Cancer

Presented by the Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing.

Supported by an educational grant from Genentech Inc.

OVERVIEW
Recent advances in immune therapy for patients with non-small cell lung cancer (NSCLC) have taken a long-awaited step forward and shifted the standard of care of patients with advanced and metastatic disease. Understanding the mechanisms of new and emerging therapies and the critical need for genomic testing are vital to implementing successful treatment of patients with this of difficult-to-treat type of cancer. Historically, NSCLC tumor cells have successfully evaded standard approaches to treatment including chemotherapy regimens and radiation therapy. Research has advanced our understanding of the tumor microenvironment and opened the door for immunotherapy treatment that engages that body’s natural immune system. Clinical trials of both approved and emerging therapies are associated with impressive responses to treatment, are answering important questions, and are providing new insight into personalizing therapy. New criteria designed to monitor patients’ tumor response to immunotherapies and aid in informing treatment are now part of the treatment paradigm. This case-based module provides education on recently approved immunotherapies and their limitations in patients with NSCLC, discusses clinical trials underway with new and emerging agents, provides insight into monitoring treatment response, and touches on considerations that may affect personalized treatment decisions and combination therapy approaches.

GOAL
The goal of this activity is to provide participants with knowledge to assist in evaluating the efficacy and safety of immunotherapies, implement genetic screening, and formulate individualized treatment plans for patients with metastatic NSCLC.

TARGET AUDIENCE
This activity is designed for oncology healthcare providers (oncologists, oncology nurses, and oncology physician assistants) who care for patients with NSCLC. No prerequisites required.

LEARNING OBJECTIVES
After participating in this activity, the participant will demonstrate the ability to:
  • EVALUATE the efficacy and safety of immunotherapy as part of NSCLC treatment paradigms.
  • FORMULATE individualized treatment plans for NSCLC using patient case scenarios.
The Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing take responsibility for the content, quality, and scientific integrity of this CME/CNE activity.

CE INFORMATION
Accreditation Statements — This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing. The Johns Hopkins University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Institute for Johns Hopkins Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation Statements — The Johns Hopkins University School of Medicine designates this enduring material for a maximum of .5 AMA PRA Category I CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This .5 contact hour educational activity is provided by the Institute for Johns Hopkins Nursing. Claim only those contact hours actually spent in the activity. Statements will be awarded for this educational activity until November 18, 2018.

Release date: November 18, 2016    Expiration date: November 19, 2018

FACULTY
Full Disclosure Policy Affecting CME Activities
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) to require signed disclosure of the existence of financial relationships with industry from any individual in a position to control the content of a CME activity sponsored by OCME. Members of the Planning Committee are required to disclose all relationships regardless of their relevance to the content of the activity. Faculty are required to disclose only those relationships that are relevant to their specific presentation.

Policy on Faculty and Provider Disclosure
It is the policy of the Institute for Johns Hopkins Nursing to require our continuing nursing education faculty and planning committee members to disclose any financial relationships with companies providing program funding or manufacturers of any commercial products discussed in the educational activity.

The following relationships have been reported for this activity:

Chair, Planner, and Faculty
David S. Ettinger, MD

Alex Grass Professor in Oncology
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Nurse Planner
Rebecca Barshick, RN, MSN

Nurse Educator
The Institute for Johns Hopkins Nursing
Baltimore, Maryland

Nurse Reviewer
MiKaela Olsen, APRN-CNS, MS, AOCNS

Oncology and Hematology Clinical Nurse Specialist
Ambulatory Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins Hospital and Greenspring Oncology Baltimore, Maryland

Planner Disclosures
Dr. Ettinger reports serving as a principal investigator for Golden Biotechnology Corp; serving on the data monitoring committee for ARIAD Pharmaceuticals Inc; and serving as a consultant for Boehringer Ingelheim, Bristol-Myers Squibb Company, Eli Lilly and Company, EMD Serono Inc, Genentech Inc. and Helsinn Therapeutics, Inc.

Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution that receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

Non-Endorsement of Products
The Institute for Johns Hopkins Nursing and the American Nurses Credentialing Center do not endorse the use of any commercial products discussed or displayed in conjunction with this educational activity.

DISCLAIMER
The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.

CONFIDENTIALITY DISCLAIMER FOR CME ACTIVITY PARTICIPANT
I certify that I am participating in this Johns Hopkins University School of Medicine activity for CME-accredited training and/or educational purposes.

I understand that while I am attending in this capacity, I may be exposed to "protected health information," as that term is defined and used in Hopkins policies and in the federal HIPAA privacy regulations (the “Privacy Regulations”). Protected health information is information about a person's health or treatment that identifies the person.

I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential. I agree not to post or discuss this protected health information, including pictures and/or videos, on any social media site (eg, Facebook, Twitter, etc.), in any electronic messaging program or through any portable electronic device.

I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone: 410-735-6509, e-mail: HIPAA@jhmi.edu.

“The Office of Continuing Medical Education at the Johns Hopkins University School of Medicine, as sponsor of this activity, has relayed information with the CME attendees/participants and certify that the visitor is here for training, education and/or observation purposes only.”

For CME questions, please contact the CME Office at 410-955-2959 or e-mail cmenet@jhmi.edu.
Johns Hopkins University School of Medicine
Office of Continuing Medical Education
720 Rutland Avenue/ Turner 20
Baltimore, Maryland 21205-2195
Reviewed & Approved by: General Counsel, Johns Hopkins Medicine (4/1/03) (Updated 4/09 and 3/14)

HARDWARE & SOFTWARE REQUIREMENTS
Pentium 800 processor or greater, Windows 98/NT/200/XP or Mac OS 9/X or later, Microsoft Internet Explorer, Safari, Firefox, Windows Media Player 9.0 or later Flash player, 128 MB of RAM Monitor settings: High color at 800 x 600 pixels, Sound card and speakers, Adobe Acrobat Reader.

THE INSTITUTE FOR JOHNS HOPKINS NURSING MISSION STATEMENT
The mission of the Institute for Johns Hopkins Nursing is to share the innovations of Johns Hopkins Nursing in practice, education, and research—locally, nationally, and globally. Our goal in continuing nursing education is to bring you activities that reflect the expertise and creativity of Johns Hopkins Nursing. Our service values are quality, integrity, flexibility, and personal attentiveness. We appreciate your thoughts and welcome your concerns—please feel free to e-mail us: IJHN@.jhmi.edu.

ACTIVITY INSTRUCTIONS
The following is an interactive case module designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited pre-test, an interactive case study, and a CME/CNE post-test and evaluation. All 3 sections must be completed to receive CME/CNE credit. A certificate of participation will be available online immediately following successful completion of the activity.

Preassessment

Considerations for Using Immune Therapy in Treating Metastatic Non-Small–Cell Lung Cancer

David S. Ettinger, MD

Postassessment and Evaluation

This activity was developed in collaboration with ASiM.


© 2017 - OncologyConsults.com